Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion. The main object of the takeover is ...

Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue ...

Merck issued a US$6bn jumbo bond on Monday to help fund its US$10.8bn acquisition of Prometheus Biosciences that will give the pharmaceutical giant a foothold in therapies for immune diseases as it ...

The startup’s management includes several from the executive team of Prometheus Biosciences, an immunology biotech bought by Merck last year.

Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals 2023 Employees say: "There's an open level of communication between execs and employees that comes with a lot of opportunity ...